IFx-Hu2.0 plus pembrolizumab for advanced or metastatic Merkel cell carcinoma
Official title: IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Run by TuHURA Biosciences, Inc. · NCT06940440 · Data updated 2026-11-12
This will test whether injecting IFx-Hu2.0 into a visceral tumor together with pembrolizumab is safe and doable for adults with advanced or metastatic Merkel cell carcinoma who have not had prior immune checkpoint inhibitors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 9 (estimated) |
| Sponsor | TuHURA Biosciences, Inc. Industry-sponsored |
| Drugs / interventions | Pembrolizumab, avelumab, ipilimumab, nivolumab, chemotherapy, prednisone |
| Locations | 2 sites (Tampa, Florida and 1 other locations) |
| Status | Recruiting |
| Started | January 27, 2026 |
| Main results expected | April 2027 |
| Study ends | May 31, 2028 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT06940440 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed recurrent or unresectable Stage III/IV Merkel cell carcinoma who are checkpoint inhibitor–naïve, have at least one visceral injectable lesion ≥3 mm, ECOG performance status <2, life expectancy ≥6 months, and adequate organ function are ideal candidates.
✕Probably not a fit
Patients who have received prior checkpoint inhibitor therapy, lack a visceral injectable lesion, have poor performance status, or have a life expectancy under six months are unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1, multicenter, open-label trial will enroll nine adults with recurrent or unresectable Stage III/IV Merkel cell carcinoma who are checkpoint inhibitor–naïve. Each participant will receive a single intralesional injection of IFx-Hu2.0 into a visceral lesion ≥3 mm followed by systemic pembrolizumab. The primary focus is on safety and feasibility, with imaging to document measurable disease and tumor tissue collection for biomarker analyses. Treatments will be administered at participating US cancer centers with scheduled follow-up for safety and response monitoring.
Why it matters
Potential benefit: If successful, adding IFx-Hu2.0 to pembrolizumab could enhance anti-tumor immune responses in visceral MCC lesions and potentially improve response rates.
How similar studies have gone: Combining intratumoral immunotherapies with PD-1 pathway inhibitors has shown promising signals in other cancers, but intralesional IFx-Hu2.0 in Merkel cell carcinoma is early-stage and largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Life expectancy equal to or greater than six months. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status \< 2. 4. Has measurable disease as defined by RECIST v1.1 5. Must be recurrent and/or unresectable Stage III or Stage IV American Joint Committee on Cancer (AJCC) (8th edition) and have histologically confirmed advanced or metastatic Merkel cell carcinoma a. Must have at least one deep-seated visceral/nodal greater than 3 mm in its longest diameter 6. Subject should be CPI naïve i.e., no prior therapy with CPI including but not limited to Pembrolizumab, avelumab, ipilimumab, nivolumab. 7. Tumor tissue from an archival core biopsy or resected site of disease must be provided for biomarker analyses. If archival tissue is not available, then a new biopsy should be performed. 8. Adequate hematological, hepatic, and renal function according to laboratory ranges and medical criteria defined within the study protocol. Exclusion Criteria 1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with protocol requirements. 2. Subjects with active brain metastases, with the exception of treated brain metastases that have imaging proving stability at least 4 weeks after treatment, no new metastases, and not requiring steroids. 3. Subjects with recurrent resectable MCC 4. Subjects who have received prior systemic chemotherapy 5. Pregnant or breastfeeding females and females desiring to become pregnant or breastfeed within the timeframe of this study. 6. Active, known, or suspected autoimmune disease. Potential subjects with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. Low grade autoimmune toxicity is NOT an exclusion under this criterion. 7. A condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of IFx-Hu2.0 administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
Where it's running
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States Recruiting -
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Andrew S Brohl, MD — Collaborator
- Study coordinator: James Bianco, MD
- Email: jbianco@tuhurabio.com
- Phone: 8138756600
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IFx-Hu2.0 with pembrolizumab for advanced or metastatic Merkel cell carcinoma
This will test whether injecting IFx-Hu2.0 into a tumor before giving pembrolizumab helps adults with advanced or metastatic Merkel cell carcinoma respond better than pembrolizumab alone.
-
Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer
This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer
This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
-
Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion
This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.